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Abstract
Both the infectious agent and development of inflammatory response to infection can
lead to irreversible myocardial injury, which affects the outcome of short- and long-term
prognosis.  In  the  case  of  the  rapid  elimination  of  the  infectious  agent  and  rapid
withholding of inflammatory process, changes in myocardium are small. If the immune
response does not lead to complete elimination of infectious agent or inflammation
progresses  after  removing  the  virus,  chronic  myocardial  damage  may  develop.
Persistence of the virus in myocardium, postinfectious immune reaction, autoimmunity,
and primary cardiac damage may result in the development of progressive ventricular
dysfunction,  development  of  cardiac  arrhythmias,  and  exacerbation  of  symptom.
Because of the long-term consequences, it is important to diagnose infective cardiomy-
opathy (IC) quickly and start appropriate treatment. However, IC is still a diagnostic
challenge.  Infective  cardiomyopathy  is  often  underdiagnosed  because  of  a  wide
spectrum of factors causing IC—infectious, toxic, immunologic, and various clinical
manifestation. The processes responsible for the development of IC take place at the
cellular level, which is why it is important to make the diagnosis not only based on
clinical  symptoms and imaging but also to confirm it  with the use of histological,
immunohistochemical, and molecular studies. Progress in the diagnosis and under-
standing of the pathomechanisms responsible for the development of IC contributed to
the  use  of  new  therapeutic  options.  Immunosuppresive  and  immunomodulative
treatment is still of limited use. However, in some cases of viral IC, targeted antiviral
treatment can be added to the standard heart failure therapy resulting in improvement
of the prognosis.
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1. Introduction
Infective cardiomyopathy (IC) is a disease in which structural or/and functional heart disorders
are observed as a result of present or past infection caused by various infectious agents. In the
course of infective cardiomyopathy heart chambers’ dilatation, heart walls’ hypertrophy or
restriction may occur. A relation between infection and chronic heart disease was suggested as
early as 1806, when Corvisart described a cardiac inflammatory disorder that could result in
progressive abnormalities of cardiac function after all the evidence of the infective agent had
disappeared [1]. Because of a variety of symptoms, diagnosis of IC can be difficult [2]. Usually,
the suspicion of IC is based on clinical presentation and results of noninvasive diagnostic imaging,
e.g., cardiac magnetic resonance (CMR) [3]. Although endomyocardial biopsy (EMB), which
can confirm myocarditis, is the gold standard in making a diagnosis, it is not often performed
because of its still low availability and invasiveness. However, the interest in this method is
increasing lately [2]. Although more is known about the pathophysiology of the disease, many
questions remain unanswered. There are many controversions about the treatment of patients
with IC, especially the most common form—viral myocarditis [3].
2. Etiology
Infective cardiomyopathy may be caused by many etiological factors including viruses,
bacteria, rickettsiae, fungi, protozoa, and parasites. However, the spectrum of pathogens has
changed over the decades and also varies geographically as, for example, Trypanosoma cruzi [4].
Moreover, it can result from noninfectious agents, such as allergic agents, autoimmunity,
toxins, and drugs [5]. Etiological factors that could cause IC are presented in Table 1.
The most popular infective agents
Viruses  RNA viruses:
Coxsackieviruses A and B, Echoviruses, Polioviruses, Influenza A and B viruses, Respiratory Syncytial
virus, Mumps virus, Measles virus, Rubella virus, Hepatitis C virus, Dengue virus, Yellow fever virus,
Chikungunya virus, Junin virus, Lassa fever virus, Rabies virus, Human immunodeficiency virus-1
DNA viruses:
Adenoviruses, Parvovirus B19, Cytomegalovirus, Human herpesvirus-6, Epstein-Barrvirus, Varicella-
zoster virus, Herpes Simplex virus, Variola virus, Vaccinia virus
Bacteria  Staphylococcus, Streptococcus, Pneumococcus, Meningococcus, Gonococcus, Salmonella,
Corynebacterium diphtheria, Haemophilus influenzae, Mycobacterium tuberculosis, Mycoplasma
pneumoniae, Brucella
Spirochete Borrelia, Leptospira
Fungi  Aspergillus, Actinomyces, Blastomyces, Candida, Coccidioides, Cryptococcus, Histoplasma,
Mucormyces, Nocardia, Sporothrix
Protozoa  Trypanosoma cruzi, Toxoplasma gondii, Entamoeba, Leishmania
Parasites  Trichella spiralis, Echinococcus granulosus, Taenia solium
Rickettsiae Coxiella burnetti, R. rickettsii, R. tsutsugamuschi
Source: Modified based on Ref. [2].
Table 1. Etiological factors of IC.
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3. Diagnostic criteria for myocarditis
The common feature of the diseases that are called “infective heart disease” is myocarditis.
Changes in myocarditis affect cardiomyocytes, interstitial tissue, vessels, and sometimes also
the pericardium. Recent prospective postmortem data have implicated myocarditis in sudden
cardiac death of young adults at rates of 8.6–12% [6, 7]. Furthermore, it has been identified as
a cause of dilated cardiomyopathy in 9% of the cases in a large prospective series [8]. The
diagnosis of myocarditis is based on histological, immunohistochemical, and immunological
criteria [4].
3.1. Histological criteria—Dallas criteria
The Dallas criteria were proposed in 1986 and provided a histopathological categorization by
which the diagnosis of myocarditis could be established (Figure 1A and B). Dallas criteria
(acute) myocarditis requires an inflammatory infiltrate and necrosis or damage of adjacent
muscle cells not characteristic of an ischemic event. Borderline myocarditis requires a less
intense inflammatory infiltrate and no light microscopic evidence of myocyte destruction [8].
The histological diagnosis of myocarditis includes different forms, classified according to the
type of inflammatory cell infiltrate: lymphocytic, eosinophilic, polymorphic, giant cell
myocarditis, and cardiac sarcoidosis. The distribution and diffusion of the cellular infiltrate
can be focal, confluent or diffuse, and mild, moderate or severe.
Figure 1. H&E staining, presenting numerous leucocytes (A) and myocyte damage (B). Immunohistochemical staining
of leucocytes (C) and CD 3 lymphocytes (D).
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3.2. Immunohistochemical criteria
The Dallas criteria are limited by the high interobserver variability in interpreting biopsy
specimens (in particular with regard to borderline myocarditis) and because noncellular
inflammatory processes cannot be detected (Figure 1C and D). Thus, immunohistochemistry
is gaining further acceptance in the diagnosis of myocarditis. Monoclonal antibodies allow the
characterization and localization of the mononuclear cell infiltrates: for example, CD3 for T
cells, CD68 for activated macrophages, and human leukocyte antigen to assess HLA class II
cells. With the use of these immunohistological methods, the number of EMB revealing
myocarditis markedly increased. According to the World Health Organization/International
Society and Federation of Cardiology Task Force on the Definition and Classification of
Cardiomyopathies, EMB is considered to be inflamed by immunohistochemical detection of
the inflammatory infiltration defined as: ≥14 leukocytes/mm2 (including ≥7 cells/mm2 CD3 +
and <4 monocytes/mm2) [2].
Histological assessment and immunohistochemical analysis of biopsy allow the determination
of the presence of inflammation in the heart. In order to determine the etiology, many frequent
further studies, including polymerase chain reaction (PCR), should be performed.
4. Viral infection
Viral infections are considered to be the main cause of myocarditis in Europe and in USA [9].
It is characterized by myocardial infiltrate with lymphocytes as the predominant inflammatory
cell (Lymphocytic (viral) myocarditis).
With the use of molecular techniques, EMB detection of viruses is possible in up to 67% of
idiopathic left ventricular dysfunction [10]. In the past, enteroviruses (especially Coxsackie B3
and B4 viruses) were assigned to be the most common cause of IC; currently, the most common
viral etiologic agents are parvovirus B19 (PVB19), human herpes virus 6 (HHV 6), and
cytomegalovirus (CMV) [5, 11]. It is still not known to what extent the presence of PVB19 and
HHV 6 genome detected in the myocardium affects the development of inflammation. The
following forms of viral heart diseases are currently distinguished based on histopathological,
genetic examinations, and results of echocardiography [12] (Table 2):
The form of heart disease caused by
viruses
Dallas and
immunohistochemical criteria
The presence of
viral genome
Dilatation of left
ventricle
Viral myocarditis with normal ejection
fraction
+ + –
Viral inflammatory cardiomyopathy + + +
Viral heart disease – + +/–
Table 2. The forms of heart diseases caused by viruses based on histopathology, genetics, and echocardiography.
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4.1. Parvovirus B19 (PVB19)
Parvovirus B19 is the most common cause of viral cardiomyopathy, both in the presence or
without inflammation. The presence of PVB19 has been observed significantly more often in
patients with an ejection fraction (EF) <45% as compared to those of EF >45% [13]. The incidence
of PVB19 DNA in patients with IC ranges from 11 to 56% according to various sources [14,
15]. The presence of PVB19 is associated with a gradual deterioration of EF, and the elimination
of PVB19 from the myocardium resulted in significant improvement of ventricular function
[16].
4.2. Human hepresvirus 6 (HHV 6)
The genome of HHV 6, beside PVB19, is now one of the most frequently detected pathogens
during EMB [11]. Its presence has been found in 11–18% of the EMB samples [10, 15]. What is
important, HHV6 can activate infections caused by other viruses such Epstein-Barr virus (EBV)
and PVB19 [17]. Both HHV 6, as well as PVB19, may remain in the infected cells for a lifetime.
Therefore, such a high proportion of the genome of the virus among patients with IC can be
associated with the previous infection [16, 18].
4.3. Enterovirus
Presently, in patients with IC, enteroviral etiology is less frequently observed. According to
various sources, enteroviral RNA is found in from 3 to 53% of the patients with IC. The majority
of data is related to Coxsackievirus B3 [16]. It is important that, in contrast to PVB19 and HHV
6, up to 50% of the patients with IC, spontaneous elimination of the enteroviral genome was
observed, with improvement of EF [11].
4.4. Adenovirus
Currently, adenovirus genome is less often detected during EMB, and it is present in <2% of
the biopsies [19]. Patients with adenovirusal IC often present only mild clinical symptoms, and
the results of biopsies analyzed according to the Dallas criteria show mild myocarditis or
borderline fulfill these criteria. Therefore, adenoviral IC may have been underestimated for
many years [20].
4.5. Cytomegalovirus (CMV)
Currently, CMV DNA is rarely detected during EMB performed in patients with myocardial
dysfunction, and the incidence is <3%; according to some sources, it is even <1% [10, 19].
However, there are reports that the presence of CMV in immunocompetent patients is
associated with the occurrence of severe IC [21].
4.6. Influenza virus
The influenza virus may also be responsible for the development of IC [20, 22, 23], and its
genome is detected in <1% of the patients with IC [16]. Infectious cardiomyopathy caused by
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influenza A virus may result in the development of heart failure, leading to patient’s death or
myocardial fibrosis with conduction defects [24]. The relationship between pandemic
influenza virus H1N1 and IC is studied carefully. There are cases of acute IC observed mainly
among young patients, which are associated with this pandemia [25].
4.7. The human immunodeficiency virus (HIV)
HIV infection may also cause myocarditis [26]. In a postmortem study of HIV-infected patients,
myocarditis was established by histopathological criteria in more than 60% of the cases.
However, most of these patients have discrete and unspecific abnormalities on the echocar-
diogram. In general, patients with advanced forms of HIV infection are subject to a high risk
of developing overt myocarditis. HIV-related myocarditis is associated with a poor prognosis,
especially in patients with low CD4+ counts (<400 cells/mm3). These high-risk patients may
develop severe left ventricular dysfunction, which could progress to advanced forms of dilated
cardiomyopathy [27]. Nevertheless, it is still discussed, whether the virus, the medical
treatment, or the coinfections are responsible for the development of IC in patients infected
with HIV [27]. It is known that the IC related to HIV infection is characterized by a significantly
worse prognosis than other lymphocytic IC [28].
4.8. Hepatitis C virus (HCV)
Hepatitis C virus is also considered to be the cause of IC [29]. HCV-associated cardiomyopathy
can develop in genetically susceptible patients infected with HCV in whom viral, immuno-
logic, and apotoptic mechanisms may lead to myocardial damage [30]. Hepatitis C virus not
only causes myocarditis but also involved in the development of dilated cardiomyopathy,
hypertrophic cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy.
Frequency of HCV genomes in cardiomyopathies varies in different regions or in different
populations. Major histocompatibility complex class II (MHC class II) genes may be important
in the susceptibility to HCV infection and may play a role in the development of different types
of cardiomyopathies. It has been suggested that interferon (IFN) treatment can be useful among
these patients [31].
4.9. Clinical presentation
Infectious cardiomyopathy can be completely asymptomatic [32]. The most common symp-
toms in patients with IC are shortness of breath, chest pain, and palpitations [33]. Often cardiac
manifestation of IC is preceded by flu-like symptoms, infection of upper respiratory tract, or
gastrointestinal tract. Fatigue, shortness of breath, palpitations, and atypical chest pain may
occur a few days or weeks later [34]. Infectious cardiomyopathy can result in development of
fulminant heart failure [27]. Since some of the symptoms may resemble acute coronary
syndrome (ACS), it is important to exclude coronary artery disease (CAD) and other diseases
of the cardiovascular system [2]. In some cases, the only abnormality may be nonspecific ECG
changes [27]. In some cases, laboratory examinations can reveal increased troponin I, troponin
T, and CK-MB, suggesting myocardial injury [35]. There are four main clinical presentations
of IC (Table 3):
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1. Acute coronary syndrome-like
2. New onset or worsening heart failure in the absence of CAD and known causes of heart
failure
3. Chronic heart failure in the absence of CAD and known causes of heart failure
4. “Life-threatening condition,” in the absence of CAD and known causes of heart failure
comprising
Clinical presentation of patients with inflammatory heart disease
1. Acute coronary syndrome-like:
a. Acute chest pain frequently presents after respiratory or gastrointestinal infection, associated with severe or
recurrent symptoms in the absence of angiographic evidence of coronary artery disease (CAD)
b. ST/T wave changes: ST-segment elevation or depression or T-wave inversion
c. With or without normal global or regional LV and/or RV dysfunction on echocardiography or CMR
d. With or without increased TnT/TnI that may have a time course similar to acute myocardial infarction or a
prolonged and sustained release over several weeks or months
2. New onset or worsening heart failure in the absence of CAD and known causes of heart failure
a. New onset or progressive heart failure over 2 weeks to 3 months
b. Impaired systolic LV and/or RV function, with or without dilated LV and/or RV on echocardiography or CMR
c. Symptoms possibly started after a respiratory or a gastrointestinal infection, or in the peripartum period
d. Nonspecific ECG signs, sometimes bundle branch block and/or ventricular arrhythmias and/or AV-block
3. Chronic heart failure in the absence of CAD and known causes of heart failure (see Point 2 above)
a. Heart failure symptoms (with recurrent exacerbations) of >3 months duration
b. Fatigue, palpitation, dyspnoea, atypical chest pain, and arrhythmia in ambulant patient
c. Impaired systolic LV and/or RV function on echocardiography or CMR suggestive of dilated cardiomyopathy or
nonischemic cardiomyopathy
d. Nonspecific ECG signs, sometimes bundle branch block and/or ventricular arrhythmias and/or AV-block
4. Life-threatening condition’, in the absence of CAD and known causes of heart failure comprising:
a. Life-threatening arrhythmias and aborted sudden death
b. Cardiogenic shock
c. Severely impaired LV function
Source: Based on Ref. [2].
Table 3. Clinical presentation of patients with IC.
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4.10. Clinicopathological classification
Myocarditis is classified based on clinical presentation, function of left ventricle, Dallas, and
immunohistochemical criteria on the following:
1. Fulminant myocarditis: a presentation with acute illness following a distinct viral
syndrome. Histological study reveals multiple foci of active myocarditis. Clinical presen-
tation consists of severe cardiovascular compromise and ventricular dysfunction. This
subgroup typically either resolves spontaneously or results in death. Fulminant myocar-
ditis in most of the cases is associated with giant cell or eosinophilic myocarditis.
2. Acute myocarditis: a presentation with insidious onset of illness and evidence of estab-
lished ventricular dysfunction. This subgroup may progress to dilated cardiomyopathy.
3. Chronic active myocarditis: a presentation with insidious onset of illness with clinical and
histological relapses with development of left ventricular dysfunction and associated
chronic recurrent inflammatory changes.
4. Chronic persistent myocarditis: a presentation with insidious onset of illness character-
ized by a persistent histological infiltrate frequently with foci of myocyte necrosis.
Clinically, no ventricular dysfunction is present despite other cardiovascular symptoms
(such as palpitations or chest pain).
4.11. Diagnostics
4.11.1. Electrocardiography
Infectious cardiomyopathy is often accompanied by nonspecific ECG abnormalities (Table 4).
The spectrum changes to include ST-segment elevation in multiple leads, generally concave,
rarely of another shape. The occurrence of atrioventricular block with a mild enlargement of
the left ventricle may suggest, e.g., IC in the course of Lyme disease, sarcoidosis, or multicel-
lular myocarditis [2]. Infectious cardiomyopathy may also result in “idiopathic” atrial or
ventricular arrhythmias and reduction of PQ-segment [36, 37]. The sensitivity of the ECG is
determined at 47%, but the specificity remains unknown [38]. It is recommended to perform
standard 12-lead ECG in patients with suspected IC [2].
4.11.2. Echocardiography
Abnormalities revealed by echocardiography are not specific for IC. However, the use of this
method allows assessing both size of heart chambers and systolic and diastolic function of the
heart in patients with IC. This modality can be also useful to exclude other causes of heart
failure, such as valvular heart disease or other forms of cardiomyopathy (hypertrophic
cardiomyopathy and restrictive cardiomyopathy). Performing echocardiography plays
especially important role in the assessment of the heart before EMB—to exclude pericardial
effusion and blood clots in the cavities of the heart, which are present in 25% of the patients
[39]. Moreover, evaluation of echocardiographic parameters has a prognostic significance.
Patients with fulminant IC often have normal heart chamber dimensions but increased
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intraventricular septum thickness due to myocardial edema, while in patients with acute IC
dilatation of left ventricle and normal wall thickness can be observed [3, 40].
Diagnostic criteria
1. ECG/Holter/stress test features
Newly abnormal 12 lead ECG and/or Holter and/or stress testing, any of the following: I to III degree atrioventricular
block, or bundle branch block, ST/T wave change (ST or non-ST elevation, T-wave inversion), sinus arrest,
ventricular tachycardia or fibrillation ora systole, atriafl fibrillation, reduced R-wave height, intraventricular
conduction delay (widened QRS complex), abnormal Q-waves, low voltage, frequent premature beats,
supraventricular tachycardia
2. Myocardiocytolysis markers
Elevated TnT/TnI
3. Functional and structural abnormalities on cardiac imaging (echo/angio/CMR) new, otherwise unexplained LV
and/or RV structure and function abnormality (including incidental finding in apparently asymptomatic subjects):
regional wall motion nor global systolic or diastolic function abnormality, with or without ventricular dilatation,
with or without increased wall thickness, with or without pericardial effusion, with or without endocavitary
thrombi
4. Tissue characterization by CMR
Edema and/or LGE of classical myocarditic pattern
Source: Based on Ref. [2].
Table 4. Diagnostic criteria for clinically suspected IC.
4.11.3. Cardiac magnetic resonance
The use of CMR, with the assessment of early gadolinium enhancement (EGE) and late
gadolinium enhancement (LGE), is helpful in making the diagnosis of IC. In T1-weighted
imaging with the assessment of the EGE, hyperintense areas show myocardium with a good
blood supply, whereas the assessment of the LGE in T1-weighted imaging allows to visualize
the irreversible myocardial injury resulting from the replacement of myocardial cells by fibrous
tissue. Scarring and fibrosis delineated with the use of LGE-imaging are hyperechoic in
contrast to normal myocardial cells. Scarring that is present in IC is located intramuscularly
(typically in chronic IC) or subepicardially (typically in acute IC) [41, 42]. Location of changes
in CMR enables to distinguish postinfarction scars that occur subendocardially or include the
entire myocardial wall from the scars arising in the course of IC. Moreover, T2-weighted
imaging reveals swelling of the myocardium, which is visible as a hyperechogenic area.
Swelling in IC can be both global and regional. It reflects the reversible myocardial damage
and can be present even in the absence of LGE hyperintense regions [43–45]. Cardiac magnetic
resonance should be performed before EMB in hemodynamically stable patients, however, in
life-threatening conditions, in which urgent EMB is necessary, it is not recommended to
perform CMR [2, 46, 47].
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4.11.4. Endomyocardial biopsy
Endomyocardial biopsy plays an important role in the diagnosis of IC. Nevertheless, in many
clinics, it is performed only in the minority of cases with a suspicion of IC or it is not performed
at all because of the lack of technical possibilities and experience. However, it is important to
perform EMB in every patient with suspected IC, as it is considered to be a gold standard in
making the diagnosis of IC [2, 3]. In the absence of feasibility of performing EMB, patients
should be transferred to a reference center [48]. According to Schultheiss, EMB should be
performed in every case of suspected IC [18, 49]. This method indicates the etiology and shows
type of inflammatory infiltration, which may have therapeutic implications. According to
Dallas criteria, making the diagnosis of acute IC is possible based on the presence of both
lymphocyte infiltration and necrosis of cardiomyocytes, while borderline IC is defined as the
presence of lympocyte infiltration and lack of cardiomyocytes necrosis [48]. Together with
molecular, histological, and immunohistochemical examinations, EMB allows to start antiviral
treatment or immunosuppression safely. Performing EMB has the highest level of recommen-
dation in life-threatening IC [46]. Endomyocardial biopsy should be performed early in the
course of a disease and at least 8–10 specimens should be taken, each 1–2 mm in size. Samples
should be examined histologically, by immunohistochemistry and for the presence of viral
genome with the use of PCR (to exclude systemic infection, it is recommended to perform viral
PCR in peripheral blood at the same time). If it is necessary, EMB should be repeated to monitor
the effectiveness of therapy or when sampling error is suspected [2].
When ≥1 clinical presentation and ≥1 diagnostic criteria are fulfilled, coronary angiography
and EMB are recommended [2].
Infectious cardiomyopathy is clinically suspected if ≥1 clinical presentation and ≥1 diagnostic
criteria from different categories are fulfilled, in the absence of:
1. angiographically detectable coronary artery disease (coronary stenosis ≥50%);
2. known pre-existing cardiovascular disease or extra-cardiac causes that could explain the
syndrome (e.g., valve disease, congenital heart disease, and hyperthyroidism). Suspicion
is higher with higher number of fulfilled criteria. If the patient is asymptomatic, ≥2
diagnostic criteria should be met [2].
4.12. Treatment
In the course of IC, cardiomyocytes can be damaged by direct action of the virus, antiviral
immune response, or autoimmune response. As the cardiomyocytes are not able to regenerate,
improvement of myocardial function mainly depends on the tissue not affected by inflamma-
tion. Response to treatment depends on the cause of IC, and the severity of irreversible changes
presents at the moment of initiation of treatment [50].
Regardless of the cause, IC therapy is based on optimal treatment of heart failure, consisting
of the use of angiotensin-converting enzyme inhibitors (ACE-I)/angiotensin receptor blockers
and/or β-adrenergic receptors’ blockers [50–52]. There are well-known studies that confirm
the efficacy of captopril and candesartan in the treatment of IC [53, 54]. Moreover, it is
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recommended to reduce physical activity during the acute phase of IC and for at least 6 months
after the onset of the disease [2].
4.12.1. Antiviral treatment
Elimination of viruses from cardiomyocytes results in decrease in the symptoms reported by
patients. It also affects the heart chambers’ size, improvement of left ventricle EF, and reduction
of long-term mortality [55]. Targeted antiviral therapy can result in total elimination of the
virus genome or, even if the total elimination is not possible, it can reduce the patient’s
complaints. Nevertheless, starting antiviral therapy is useful only early in the course of a
disease, when irreversible changes in the myocardium are not present yet [18]. In IC caused
by HHV6, valacyclovir, and ganciclovir can be used [2, 17]. The use of interferon β (IFN-β)
enables to eliminate adenoviruses and enteroviruses from cardiomyocytes, improving also
heart efficiency. After treatment with IFN-β, increase in EF, decrease in left ventricle, reduction
in heart failure symptoms, and smaller inflammatory infiltration were observed [55]. Interferon
β can also be used in IC caused by PVB19—it can reduce the symptoms and endothelium
dysfunction, but it has only little effect on the elimination of the virus [18]. Mechanism of
beneficial clinical effects of IFN-β is not known, but IFN-β inhibits reactivation of PVB19 and
improves the viability of endothelial cells [56]. Similarly, in IC caused by HHV6, treatment
with IFN-β or ganciclovir does not eliminate virus from the myocardial tissue, probably
because of viral genome integration with host genome. However, in patients with HHV6, IC
ganciclovir reduces clinical symptoms [57].
4.12.2. Immunosuppression
Immunosuppression with the use of steroids, combination of steroids and azathioprine or
azathioprine, cyclosporine A, and steroids is safe and efficient in IC. So far there is no data
about the use of other Immunosuppresive drugs in IC treatment [2]. It is important to perform
EMB before initiation of immunosuppression to exclude viral etiology of IC [50] because only
patients with autoimmune IC benefit from immunosuppression [58–60]. Therefore, immuno-
suppression should be considered in patients with autoimmune IC, including giant-cell IC,
sarcoidosis, IC in the course of “noncardiac” autoimmune diseases, who do not have contra-
indications for immunosuppressive therapy. The use of steroids is indicated in sarcoidosis with
ventricle dysfunction and/or arrhythmia and in some cases of noninfectious eozynophilic IC
or toxic IC with concomitant heart failure and/or arrhythmia. When there are no contraindi-
cations, immunosuppression can be also considered in noninfectious lymphocytic IC resistant
to standard therapy [2].
4.12.3. High-dose intravenous immunoglobulin
No consensus exists on the benefits of high-dose intravenous immunoglobulin (IVIG) in the
treatment of IC. Although there are reports confirming the improvement of left ventricular
function and increase in one-year survival after application of IVIG [61], finally, it appears that
this therapy has no positive effect on progression of IC [62, 63].
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4.12.4. Immunoabsorption
The aim of immunoabsorption (IA) is elimination of antibodies against cardiac proteins [64].
There are some studies that confirm the efficacy of IA in dilated cardiomyopathy [65, 66].
However, multicenter, randomized studies are needed to recommend the use of IA in a
standard IC therapy.
5. Other heart infections
5.1. Bacterial infections
Bacterial myocarditis with no coexisting endocarditis occurs extremely rarely. Usually, it
results from massive bacteremia. Staphylococcus aureus is a main etiological factor of bacterial
myocarditis. Nevertheless, cardiac involvement in the course of streptococcal (Streptococcus
pyogenes, Streptococcus viridans, and Streptococcus pneumoniae) infection has also been reported
[67]. Moreover, myocarditis can be the result of meningococcal disease or can be associated
with Salmonella, Listeria monocytogens, or Corynebacterium diphtheria infection [68–71]. Bactere-
mia, neutropenia, myocardial infarction, osteomyelitis, and recent surgical procedures are
considered to be main risk factors of bacterial myocarditis. Clinical manifestation is dominated
by sepsis and heart failure symptoms. To confirm the diagnosis, EMB should be performed,
revealing active myocarditis with evidence of bacterial invasion or positive tissue cultures [71].
Standard treatment consists of aggressive targeted antibiotic or antitoxin therapy and appro-
priate hemodynamic support, in conjunction with the treatment of arrhythmias or mechanical
complications [67, 71].
5.1.1. Mycobacterium tuberculosis
Myocarditis is a very rare manifestation of Mycobacterium tuberculosis infection. There are
three types of myocardial tuberculosis: nodular tubercles of the myocardium, miliary tubercles
of the myocardium, and diffuse infiltrative type associated with tuberculous pericarditis.
Cardiac tissue can be infected by hematogenous spread, by retrograde lymphatic spread from
mediastinal lymph nodes, or directly from the pericardium. In patients with strong suspicion
of cardiac tuberculosis, EMB should be performed to confirm the diagnosis. Clinical presen-
tation is nonspecific and varies from ventricular fibrillation, long QT syndrome, congestive
heart failure, and DCM to sudden cardiac arrest. However, a large number of patients are
completely asymptomatic. Anti-tuberculosis therapy is usually effective; nevertheless, it does
not reduce the risk of sudden cardiac death [72].
5.1.2. Tropheryma whipplei
Whipple’s disease is a rare bacterial infection, which usually affects the intestinal tract, but it
can also involve other organs. Cardiac manifestation of Whipple’s disease occurs in 35–60% of
affected patients. Infectious endocarditis with negative blood cultures develops most com-
monly. Whipple’s disease may also present as adhesive pericarditis and myocardial fibrosis.
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Lymphocytic myocarditis is unusual [73]. Cardiac involvement can clinically present as
congestive heart failure, conduction disturbances, arrhythmias, or even sudden cardiac death.
It is suggested that chronic damage of heart tissue is the cause of death in most patients with
end-stage disease [74]. It is difficult to confirm the diagnosis due to lack of culture and
serodiagnostic methods. Currently, detection of T. whipplei by PCR is a method of choice to
establish the diagnosis. Treatment of Whipple’s disease remains empirical; it is suggested to
use trimethoprim-sulfamethoxazole for at least 1 year, or, alternatively, an initial parenteral
therapy with penicillin and streptomycin for 2 weeks followed by trimethoprim-sulfamethox-
azole [73].
5.2. Spirochetes infection
5.2.1. Borrelia burgdorferi
Lyme disease (LD) that is caused by B. burgdorferi mostly affects skin, heart, nervous system,
and joints [75]. The most common cardiac manifestation of LD is conduction and rhythm
disturbances, most frequent of which is atrioventricular (AV) block [76]. However, LD can also
result in myocarditis and new-onset of DCM, especially in the highly endemic area for LD [75,
77]. Serological diagnosis in patients with cardiac LD may be difficult, as IgM and IgG
antibodies against B. burgdorferi are frequently negative at first; a measurable level of antibodies
develops in the course of illness [75, 78]. Therefore, EMB can be extremely useful in making
the diagnosis of DCM caused by B. burgdorferi [79]. Early treatment with antibiotic therapy
(intravenous infusion of ceftriaxone) is effective and leads to significant improvement of left
ventricle ejection fraction and reduction of heart failure symptoms [75, 79].
5.3. Fungal infection
Fungal myocarditis mostly develops in immunodeficient patients. Therefore, it can be often
clinically latent or masked by neurological or respiratory symptoms [80].
5.3.1. Aspergillus
Cardiac aspergillosis occurs mostly in patients with immunodeficiency or immunosuppres-
sion such as cancer, hematological conditions, or organ transplantation. Cardiac involvement
occurs as a result of disseminated Aspergillus infection. It is associated with high mortality rate
because of late diagnosis and lack of effective therapy [81].
5.3.2. Blastomycosis
Cardiac blastomycosis can develop by an extension from pericardial blastomycosis, by a direct
involvement of heart tissue, or by a lymphatic spread from mediastinal lymph nodes. It often
leads to congestive heart failure, with heart chambers dilatation and little hypertrophy. The
course of cardiac blastomycosis has many common features with cardiac tuberculosis [82].
Infective Cardiomyopathy
http://dx.doi.org/10.5772/66095
203
5.3.3. Candida
Candida is not pathogenic among immunocompetent hosts, but it can cause severe mucosal or
systemic infections in immunocompromised patients [83]. Candida invasion of the heart
significantly complicates the clinical course of candidiasis and aggravates the patients’
condition and should be suspected when arrhythmia, conduction disturbance, or other QRS
changes occur in patients with systemic candidiasis [84].
5.4. Protozoan infections
5.4.1. Trypanosoma cruzi
Chagas disease is caused by infection with Trypanosoma cruzi (T. cruzi), which is transmitted
by blood-sucking insects and small mammals. The disease is common in the southwestern part
of United States, Mexico, Central, and South America [85]. Contact of skin lesions, mucosal
surfaces, or the conjunctiva with parasites present in the feces of the insect leads to infection
with T. cruzi. In nonendemic countries, transmission is also possible with blood transfusion,
organ transplantation, and vertical way [86].
In the course of Chagas disease, two phases are described: an acute and a chronic phase [86].
Patients with acute Chagas disease may present nonspecific symptoms or may be completely
asymptomatic. Moreover, acute myocarditis, pericardial effusion, and/or meningoencephalitis
can develop in the course of acute infection [85]. In a majority of patients, the acute phase
subsides spontaneously after 6–8 weeks [86]. In some of the infected patients, chronic Chagas
disease develops with the symptoms from various organs [86]. Patients with chronic Chagas
cardiomyopathy can present symptoms of heart failure, arrhythmias, thromboembolism
(systemic or pulmonary), and chest pain [85]. Echocardiography may be useful in making the
diagnosis of Chagas cardiomyopathy. It can reveal a specific pattern of segmental myocardial
contractility disturbance, mainly localized in left ventricular apex and inferior-posterior wall
[86]. Moreover, in chronic Chagas cardiomyopathy, echocardiography can show severe
dilation of the heart chambers characteristic aneurysm localized in left ventricle’s apex [85].
Because of high risk of thromboembolism, transesophageal echocardiography can be helpful
to identify cardiac sources of emboli and make decision about anticoagulant treatment [85].
Histopathologically myocytolysis, reparative fibrosis, and lymphocytic infiltrates are seen in
Chagas heart disease. Treatment of Chagas cardiac disease consists of targeted antiparasitic
therapy and treatment of heart failure, arrhythmias, and thromboembolism [86]. Benznidazole
is used to eliminate T.cruzi, and it is effective in acute phase [87]. Its efficacy in chronic Chagas
cardiomyopathy is still discussed [86]. Angiotensin-converting enzyme (ACE) inhibitors and
β-blockers can be useful in heart failure therapy. Because of high risk of thromboembolism in
Chagas disease, oral anticoagulation should be considered with cardioembolic risk score for
Chagas disease patients [86]. Moreover, pacemaker or ICD implantation may contribute to a
better survival in some patients with Chagas disease [87].
Cardiomyopathies - Types and Treatments204
5.5. Parasitic infection
5.5.1. Echinococcus
Echinococcal infection develops after consumption of Echinococcus eggs from the feces of
infected dogs or other canids. In the majority of cases, the disease involves liver or lungs. Heart
is a very rare localization of parasites’ cysts. Cardiac echinococcosis can manifest as arrhyth-
mias, myocardial infarction, cardiac tamponade, pulmonary hypertension syncope, purulent
pericarditis, and sudden cardiac death. The basis of making the diagnosis is serology and
echocardiography, which can visualize myocardial or pericardial hydatid cysts. Moreover,
with the use of CMR or computed tomography calcification of the cysts’ walls can be shown.
Albendazole or mebendazole should be used in the treatment of cardiac echonococcosis [88].
6. Autoimmune heart inflammation
6.1. Sarcoidosis
Sarcoidosis is a systemic granulomatous disease of unknown etiology. Clinical presentation
varies among patients. Sarcoidosis mostly affects skin, lymph nodes, lungs, eyes, and the
central nervous system. Cardiac involvement will occur in approximately 5% of the patients
with sarcoidosis [89] and varies in the different geographical regions, but it is considered to be
very important prognostic factor in this disease [90]. Cardiac sarcoidosis may present as acute
heart failure, ventricular arrhythmia, conduction disturbances, and even sudden death.
Diagnosing cardiac sarcoidosis may be difficult due to nonspecific ECG and echocardiographic
findings; therefore, it is often misdiagnosed. To make the right diagnosis, the use of endo-
myocardial biopsy (EMB), cardiac magnetic resonance (CMR), and 18F-fluorodeoxyglucose
positron emission tomography may be helpful. Patients should be treated with corticosteroids,
which help to control inflammatory process, prevent fibrosis, and protect from aggravation of
the cardiac function [90].
6.2. Churg-Strauss syndrome (CSS)
Churg-Strauss syndrome is a rare systemic vasculitis, which affects small- and medium-sized
blood vessels, characterized by eosinophil infiltration of various tissues [91]. It occurs in
patients with an atopic condition, typically with a previous history of asthma or allergy disease.
According to different sources, cardiac involvement is reported in 16–92% of patients with
CCS [92, 93]. Cardiac changes are associated with a poor prognosis and high mortality, if not
treated [94]. There are two types of cardiac involvement in CSS: vasculitis-related ischemia and
eosinophilic infiltration of the myocardium. It can present as myocarditis with cardiomyop-
athy, pericarditis, pericardial effusion, heart failure, ventricular and supraventricular arrhyth-
mias, and sudden cardiac death. Heart involvement is characterized by both fibrosis and an
active inflammatory process. Changes visualized by CMR with LGE are mostly localized in
the subendocardium [95, 96], but they can be also observed in the intramural and subepicardial
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myocardium [97]. Patients with cardiac involvement are mainly antineutrophil cytoplasmic
antibody (ANCA)-negative. The management of myocarditis in the course of CCS includes
standard therapy for heart failure and immunosuppressive treatment with steroids [98].
Initiation of treatment allows recovery of cardiac function and reduces symptoms of heart
failure.
6.3. Systemic lupus erythematosus (SLE)
Systemic lupus erythematosus is an autoimmune disease, which usually occurs in young
females. Cardiac involvement is one of the most frequent manifestations. All anatomical heart
structures can be affected: pericardium, myocardium, valves, coronary arteries, and the
conduction system [99]. Several autoantibodies, such as anti-phospholipid antibodies (aPL),
anti-SSA/Ro antibodies, and anti-endothelial cells antibodies, can contribute to heart damage
in SLE. Antibodies-SSA/Ro and anti-SSB/La antigens are responsible for the development of
heart conduction disorders in the neonatal lupus syndrome.
Myocarditis is uncommon, but a serious presentation of SLE can lead to cardiac dysfunction
or even sudden cardiac death [100]. Early diagnosis of lupus myocarditis is important because
of the likely progression to arrhythmias, conduction disturbances, dilated cardiomyopathy,
and heart failure [101]. Echocardiography is a sensitive and specific technique, and it can not
only reveal global hypokinesis in patients with SLE myocarditis but also visualize other cardiac
manifestations of SLE, such as pericarditis or valvular lesions [102]. In patients with lupus
myocarditis, CMR shows LGE; however, it cannot differentiate these changes from myocarditis
of other etiology [99]. Therefore, endomyocardial biopsy is the gold standard technique in
making the diagnosis [103]. Histopathological examination shows immune complexes with
mononuclear cell infiltrates, perivascular inflammation or arteriopathy, and necrosis of the
cardiomyocytes [99]. Early treatment with high-dose steroids is the basis of lupus myocarditis
therapy. In severe cases, intravenous pulse corticosteroid should be administered. Azathio-
prine, cyclophosphamide, or intravenous immunoglobulines (IVIG) may be useful [103].
7. Summary
Both the infectious agent and development of inflammatory response to infection can lead to
irreversible myocardial injury, which affects the outcome of short- and long-term prognosis.
In the case of the rapid elimination of the infectious agent and rapid withholding of inflam-
matory process, changes in myocardium are small. If the immune response does not lead to
complete elimination of infectious agent or inflammation progresses after removing the virus,
chronic myocardial damage may develop. Persistence of the virus in myocardium, postinfec-
tious immune reaction, autoimmunity, and primary cardiac damage may result in the devel-
opment of progressive ventricular dysfunction, development of cardiac arrhythmias, and
exacerbation of symptoms [18]. Because of long-term consequences, it is important to diagnose
IC quickly and start appropriate treatment. However, IC is still diagnostic challenge.
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Infective cardiomyopathy is often underdiagnosed because of a wide spectrum of factors
causing IC—infectious, toxic, immunologic, and various clinical manifestations [3]. The
processes responsible for the development of IC take place at the cellular level, which is why
it is important to make the diagnosis not only based on clinical symptoms and imaging but
also to confirm it with the use of histological, immunohistochemical, and molecular studies
[18]. Progress in the diagnosis and understanding of the pathomechanisms responsible for the
development of IC contributed to the use of new therapeutic options. Immunosuppresive and
immunomodulative treatment is still of limited use [2]. However, in some cases of viral IC,
targeted antiviral treatment can be added to standard heart failure therapy resulting in
improvement of the prognosis [18].
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